Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for ARCT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 171.81M
March 31, 2026 191.36M
December 31, 2025 213.98M
September 30, 2025 224.56M
June 30, 2025 231.05M
March 31, 2025 233.76M
December 31, 2024 240.98M
September 30, 2024 261.87M
June 30, 2024 258.58M
March 31, 2024 263.97M
December 31, 2023 278.51M
September 30, 2023 280.06M
June 30, 2023 285.18M
March 31, 2023 329.25M
December 31, 2022 270.31M
September 30, 2022 145.67M
June 30, 2022 170.72M
March 31, 2022 184.75M
December 31, 2021 228.21M
September 30, 2021 259.13M
June 30, 2021 305.65M
March 31, 2021 352.61M
December 31, 2020 396.55M
September 30, 2020 261.63M
June 30, 2020 93.42M
Date Value
March 31, 2020 16.98M
December 31, 2019 25.79M
September 30, 2019 35.90M
June 30, 2019 21.62M
March 31, 2019 6.354M
December 31, 2018 13.64M
September 30, 2018
June 30, 2018
March 31, 2018
December 31, 2017 33.79M
September 30, 2017 38.29M
June 30, 2017 40.69M
March 31, 2017 44.23M
December 31, 2016 47.23M
September 30, 2016 52.62M
June 30, 2016 59.78M
March 31, 2016 64.99M
December 31, 2015 69.33M
September 30, 2015 35.08M
June 30, 2015 38.76M
March 31, 2015
December 31, 2014 19.94M
September 30, 2014 25.96M
June 30, 2014 35.42M
March 31, 2014 42.26M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Exelixis, Inc. 1.844B
PTC Therapeutics, Inc. -165.36M
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M

Shareholders Equity (Quarterly) Related Metrics